ABL BIO
ABL Bio is one of the world's leading biotech research companies focusing on the development of therapeutic drugs for immuno-oncology & neurodegenerative diseases. Their core values are life-improvement, collaboration, innovation and novel therapy.
ABL BIO
Industry:
Biotechnology Health Care Medical
Founded:
2016-01-01
Address:
Seongnam, Kyonggi-do, South Korea
Country:
South Korea
Website Url:
http://www.ablbio.com
Total Employee:
11+
Status:
Active
Contact:
(82)10-9191-5219
Total Funding:
90.81 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF Google Analytics Google Tag Manager Google Universal Analytics Apache Global Site Tag Mobile Non Scaleable Content Euro
Similar Organizations
Scholar Rock
Scholar Rock is a biopharmaceutical company that develops and discovers new medicines and treatments for the serious diseases.
Current Employees Featured
Founder
Investors List
DS Asset Management
DS Asset Management investment in Series C - ABL Bio
Alpen Route Asset Management
Alpen Route Asset Management investment in Series C - ABL Bio
QUAD Investment Management
QUAD Investment Management investment in Series C - ABL Bio
Hana Financial Investment
Hana Financial Investment investment in Series C - ABL Bio
DSC Investment
DSC Investment investment in Series B - ABL Bio
Global Bio Growth First Private Equity Investment
Global Bio Growth First Private Equity Investment investment in Series B - ABL Bio
Korea Investment Securities
Korea Investment Securities investment in Series B - ABL Bio
Korea Investment Partners
Korea Investment Partners investment in Series B - ABL Bio
HantuPa
HantuPa investment in Series A - ABL Bio
DSC Investment
DSC Investment investment in Series A - ABL Bio
Official Site Inspections
http://www.ablbio.com Semrush global rank: 5.7 M Semrush visits lastest month: 1.47 K
- Host name: 210.116.91.244
- IP address: 210.116.91.244
- Location: South Korea
- Latitude: 37.5112
- Longitude: 126.9741
- Timezone: Asia/Seoul
More informations about "ABL Bio"
ABL Bio
Our Core Values. ABL Bio is a research-led biotechnology company, a pioneer in bispecific antibodies for immuno-oncology and neurodegenerative diseases. Delivering new approaches …See details»
ABL Bio, Inc. - Drug pipelines, Patents, Clinical trials - Synapse
Www.ablbio.com. Public Company | 2016 | Gyeonggi-do, South Korea | 100-250 | KRX: 298380 | www.ablbio.com. Last update 01 Nov 2024. Overview. Pipeline. Deal. Translational Medicine. …See details»
ABL Bio - Crunchbase Company Profile & Funding
ABL Bio is a biotech research company that focuses on the development of therapeutic drugs for immuno-oncology and neurodegenerative diseases.See details»
ABL Bio
Ablbio medicine for a better Life South Korea's no.1 in bispecific antibody technology Outstanding R&D Personnel New Business Model through open innovation Innovation platforms & …See details»
ABL Bio Inc. | LinkedIn
ABL Bio Inc. | 1,716 followers on LinkedIn. A global leader in bispecific antibody therapeutics for immuno-oncology and neurodegenerative diseases. | ABL Bio Inc. (Kosdaq: 298380) is a …See details»
ABL Bio Company Profile 2024: Stock Performance & Earnings
ABL Bio General Information Description. ABL Bio Inc is a Korean biotech research company. The company is engaged in the development of therapeutic drugs for immuno-oncology and …See details»
[INTERVIEW] ABL Bio has grown from go-getter to go-to company
Jun 20, 2022 I think this is a good phenomenon. For Korean biopharmaceutical giants, their business sectors can be largely divided into three directions: Samsung Biologics and Lotte …See details»
ABL Bio - Craft
Mar 30, 2020 ABL Bio is a biotech research company focusing on the development of therapeutic drugs for immuno-oncology and neurodegenerative disease. It offers a range of …See details»
Blood–brain barrier molecular carriers for Parkinson’s disease
ABL Bio Inc. Sang Hoon Lee, Founder and CEO,ABL Bio Inc., Seongnam, South Korea, Tel: +82 10 4104 0861Website: www.ablbio.comSee details»
ABL Bio Enters Global Collaboration and License Agreement with …
Jan 11, 2022 /PRNewswire/ -- ABL Bio, Inc. (KOSDAQ: 298380), a clinical-stage biotech developing bispecific antibody technology for immuno-oncology and neurodegenerative...See details»
Biocytogen Enters Collaboration with ABL Bio to Develop New …
Beijing, China, March 25, 2024 –Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315), a global biotechnology company that drives the research and development of …See details»
Pipeline - ABL Bio
ABL501. Pipeline ABL501; Program Target PD-L1 x LAG-3; Disease Indication Solid Tumor; Development Stage Clinical Development (Phase 1) Summary ABL501 is a bispecific antibody …See details»
ABL Bio Enters Global Collaboration and License ... - Markets Insider
Jan 11, 2022 ABL and SANOFI to collaborate on the development of ABL301, a potential first-in-class bispecific antibody targeting alpha-synuclein and containing a proprietary brain shuttle, …See details»
Blood–brain barrier molecular carriers for Parkinson’s disease
Www.ablbio.com Figure 1: Molecular carriers crossing the blood–brain barrier (BBB). ABL301 penetrates brain epithelial cells, via an undisclosed receptor-mediated transcytosis (RMT) …See details»
ABL Bio Expands Strategic Collaboration with WuXi Biologics and ...
Feb 26, 2019 SHANGHAI and SEOUL, Feb. 25, 2019 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global open-access biologics technology platform company offering …See details»
Bispecific antibodies and novel immune cell targets for immuno
Email: [email protected] contact Fig. 2 | T cell engager BsAbs are designed to activate immune cells in the TME only. T cell engager bispecific antibodies (BsAbs) bind to tumor …See details»
ABL Bio
Oct 28, 2024 2024-11-13 ablbio ABL Bio will Present Bispecific ADC development strategy at World ADC San Diego - The company aims to be the leader of the bispecific ADC market ABL …See details»
ABL Bio Announces Publication of Preclinical Data Demonstrating …
Jul 9, 2021 ABL Contacts. Investor Inquiries. Hyunjun Kim. [email protected] +82 31 8018 9845See details»
Investors & Media - ABL Bio
2021-11-05 ablbio - ABL602 is a CLL-1/CD3 bispecific antibody for acute myeloid leukemia - Preclinical data highlight potential of ABL602 as a new treatment for AML . November 5, 2021, …See details»